Literature DB >> 14973946

Gamma and other cephalocondylic intramedullary nails versus extramedullary implants for extracapsular hip fractures.

M J Parker1, H H G Handoll.   

Abstract

BACKGROUND: Cephalocondylic intramedullary nails, which are inserted proximally to distally (cephalocondylic), have been used for the surgical treatment of extracapsular hip fractures.
OBJECTIVES: To compare all cephalocondylic intramedullary nails with extramedullary implants for the surgical treatment of extracapsular hip fractures in adults. This is the fourth substantive update of our original review which compared the Gamma nail with the sliding hip screw (SHS). SEARCH STRATEGY: We searched the Cochrane Musculoskeletal Injuries Group trials register, MEDLINE, several orthopaedic journals and conference proceedings, and reference lists of relevant articles. We contacted trialists, colleagues and implant manufacturers. Date of the most recent search: May 2003. SELECTION CRITERIA: All randomised and quasi-randomised trials comparing cephalocondylic nails with extramedullary implants for extracapsular hip fractures. DATA COLLECTION AND ANALYSIS: Both reviewers independently assessed trial quality and extracted data. Additional information was sought from all trialists. Wherever appropriate and possible, results were pooled. MAIN
RESULTS: Eighteen trials comparing the Gamma nail with the SHS were included, with data available for 2575 patients. The Gamma nail was associated with an increased risk of operative and later fracture of the femur and an increased re-operation rate. There were no major differences in the incidence of wound infection, mortality or medical complications between implants. Data were inadequate for other outcomes. Five trials involving 623 patients compared the intramedullary hip screw (IMHS) with the SHS. Fracture fixation complications were more common in the IMHS group: all cases of operative and later fracture of the femur occurred in this group. Results for post-operative complications, mortality and functional outcomes were similar in the two groups. One trial of 206 patients with a trochanteric fracture showed no advantages for proximal femoral nail (PFN) compared with the SHS. One trial of 60 patients reported favourable preliminary results for an experimental mini-invasive static intramedullary nail compared with the SHS. One trial of 230 patients, which compared the Kuntscher-Y nail with the SHS, reported no major difference in outcome aside from a significantly increased number of patients with leg shortening, and a tendency for poorer recovery of mobility in the Kuntscher-Y nail group. Two trials, involving 65 patients with reverse and transverse fractures at the level of the lesser trochanter, compared an intramedullary nail (Gamma or PFN nail) with an extramedullary implant (a 90-degree blade plate or dynamic condylar plate). The intramedullary nails were associated with better intra-operative results and fewer fracture fixation complications for these rare fractures. REVIEWER'S
CONCLUSIONS: Given the lower complication rate of the SHS in comparison with intramedullary nails, it appears that the SHS is superior for trochanteric fractures. Further studies are required to determine if different types of intramedullary nail produce similar results, or if intramedullary nails have advantages for selected fracture types (for example, reversed fracture lines and subtrochanteric fractures).

Entities:  

Mesh:

Year:  2004        PMID: 14973946     DOI: 10.1002/14651858.CD000093.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  12 in total

Review 1.  Best practices for elderly hip fracture patients. A systematic overview of the evidence.

Authors:  Lauren A Beaupre; C Allyson Jones; L Duncan Saunders; D William C Johnston; Jeanette Buckingham; Sumit R Majumdar
Journal:  J Gen Intern Med       Date:  2005-11       Impact factor: 5.128

2.  Are short femoral nails superior to the sliding hip screw? A meta-analysis of 24 studies involving 3,279 fractures.

Authors:  Henry Wynn Jones; Philip Johnston; Martyn Parker
Journal:  Int Orthop       Date:  2006-02-22       Impact factor: 3.075

3.  A meta-analysis of the Gamma nail and dynamic hip screw in treating peritrochanteric fractures.

Authors:  Ming Liu; Zhiming Yang; Fuxing Pei; Fuguo Huang; Shiqiang Chen; Zhou Xiang
Journal:  Int Orthop       Date:  2009-04-29       Impact factor: 3.075

4.  3066 consecutive Gamma Nails. 12 years experience at a single centre.

Authors:  Alicja J Bojan; Claudia Beimel; Andreas Speitling; Gilbert Taglang; Carl Ekholm; Anders Jönsson
Journal:  BMC Musculoskelet Disord       Date:  2010-06-26       Impact factor: 2.362

5.  [Complications after pertrochanteric fractures].

Authors:  B Füchtmeier; F Gebhard; A Lenich
Journal:  Unfallchirurg       Date:  2011-06       Impact factor: 1.000

Review 6.  [Trochanteric femoral fractures: anatomy, biomechanics and choice of implants].

Authors:  F Bonnaire; T Lein; P Bula
Journal:  Unfallchirurg       Date:  2011-06       Impact factor: 1.000

Review 7.  Condylocephalic nails versus extramedullary implants for extracapsular hip fractures.

Authors:  M J Parker; H H Handoll; S Bhonsle; W J Gillespie
Journal:  Cochrane Database Syst Rev       Date:  2000

Review 8.  Proximal femoral fractures: Principles of management and review of literature.

Authors:  Ravi Mittal; Sumit Banerjee
Journal:  J Clin Orthop Trauma       Date:  2012-06-16

9.  Simultaneous bilateral extracapsular proximal femur fractures in the elderly. A case report.

Authors:  Patricia Rodríguez-Zamorano; María Galán-Olleros; Javier Garcia-Coiradas; Sergio Llanos; José Antonio Valle-Cruz; Fernando Marco
Journal:  J Surg Case Rep       Date:  2022-07-05

10.  High risks of failure observed for A1 trochanteric femoral fractures treated with a DHS compared to the PFNA in a prospective observational cohort study.

Authors:  Max P L van der Sijp; Marianne de Groot; Sven A Meylaerts; Karel J du Pré; Sander M Verhage; Inger B Schipper; Arthur H P Niggebrugge
Journal:  Arch Orthop Trauma Surg       Date:  2021-02-26       Impact factor: 2.928

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.